Research topics
Microbiome articles covering gut bacteria, microbial changes, microbiota research, and IBD disease mechanisms.
Page 10 of 12 · 570 articles
This study suggests a specific gut microbe might reduce gut inflammation in a mouse colitis model and may boost the benefit of infliximab, which could point toward microbiota‑based adjuncts to current IBD therapies.
This preclinical study reports that an extract of Anacyclus pyrethrum reduced colitis signs in a mouse DSS model and was linked to improved intestinal barrier markers, lower innate immune receptor expression, changes in...
Researchers are exploring plant polyphenols and new oral delivery systems that might reduce gut inflammation and modify microbiota — findings in mice suggest potential but are not directly applicable to patients yet.
Anti-drug antibodies can make anti-TNF biologics stop working for people with Crohn’s disease. This trial tests a simple, short antibiotic course given before starting anti-TNF therapy to see if it lowers antibody...
People with IBD may be interested because the review identifies polysaccharides from traditional Chinese medicine as a potential source of new therapies that act on gut microbes, the intestinal barrier, and immune...
Cure8 could only read part of this source from Перспективи та інновації науки, so this card uses cautious topic tags instead of a full summary. It is tagged for Microbiome and Research and clinical trials.
The study points to a new local mechanism—ferroportin in colon macrophages—that links iron handling, the microbiome, and mucosal healing. If validated, this could lead to targeted treatments that help healing without...
The work suggests soluble factors present in fecal filtrates from active UC patients can provoke proinflammatory responses in a controlled intestine-on-chip model, supporting the idea that microbiome-derived metabolites...
Low-FODMAP diets are commonly used to reduce GI symptoms in IBS and sometimes in UC.
The study identifies a probiotic species (B. pseudolongum) and its acetate production as potential ways to limit a genotoxic E. coli and reduce inflammation in a mouse model — suggesting a microbiome-based avenue that...
Vitamin D deficiency is common in people with IBD and may relate to disease activity, complications, and quality of life; understanding this link could influence monitoring and adjunctive care.
The work links a missing bacterial metabolite (HDCA) to macrophage metabolism and reduced intestinal inflammation in experimental models, highlighting a potential microbiome-derived pathway that could be targeted for...
TRPV channels are proposed as integrative mediators of inflammation, angiogenesis, and oxidative stress in IBD, suggesting new mechanistic targets that could eventually yield novel therapies for Crohn's disease and...
The study identifies a natural compound that reduced inflammation and improved multiple aspects of intestinal barrier function in a zebrafish IBD model, suggesting a new candidate for preclinical drug discovery relevant...
The report suggests a probiotic (VSL#3TM) added to vedolizumab may speed or increase early response in ulcerative colitis, which could interest patients and clinicians seeking ways to improve biologic induction outcomes....
The study suggests that combining different fermentable fibers may steer the gut microbiome toward more butyrate-producing bacteria and away from pro-inflammatory lineages—changes that could be relevant to IBD-related...
The paper highlights how the gut microbiome and environment can strongly influence colitis severity in genetically susceptible mice, illustrating a gene–environment–microbiome axis that may help explain heterogeneity in...
This NIH-funded project identifies probiotic metabolic pathways that protect gut barrier integrity in a diet-dependent way, which could explain mixed clinical trial results and point to biomarkers to select patients...
This project explores how gut microbes and bile acids interact to shape immune cells in the ileum — a process that may affect inflammation in Crohn’s disease and other IBDs. Understanding these mechanisms could point to...
The study identifies a fungal β-glucan that reduced inflammation and altered the gut microbiome and short-chain fatty acids in a mouse model of ulcerative colitis, which could inform future nutritional or therapeutic...
Altered NAD metabolism may influence inflammation and tissue repair in IBD; understanding host and microbial contributions could open new research directions for metabolic biomarkers or therapeutic targets.
This matters because identifying microbiome patterns linked to infliximab response could help predict which children with IBD are more likely to benefit from the drug and guide personalized treatment decisions in the...
Nanotechnology is being heavily explored as a way to improve drug targeting, control release, and reduce systemic toxicity in IBD — topics that could shape future treatment options and research priorities.
The paper identifies microbiome-derived peptides that can directly block TLR4 signaling and reduce intestinal inflammation in mice; this reveals a new microbiome–immune mechanism that could inform future IBD treatments.
The study suggests that in IBD the gut microbiome’s functional impact on immune signalling is shifted toward inflammation even when composition appears similar to controls.
Mitochondrial dysfunction may contribute to IBD symptoms and disease progression; therapies that protect or restore mitochondrial function could become future treatment strategies. People interested in complementary or...
This trial is testing whether a rectally delivered probiotic can change the gut microbiome and promote mucosal healing in people with mild-to-moderate ulcerative colitis (and includes some Crohn's patients). If...
Researchers report links between copper-driven cell death pathways and IBD biology; identifying cuproptosis-related biomarkers or drugs could open new diagnostic or therapeutic avenues for people with Crohn's disease or...
This study looks at how statistically "fragile" results are in trials of new IBD treatments. Patients and clinicians should know that trial size, treatment type, and whether the result was a primary outcome affect how...
If you or your clinician are considering dietary therapy like the CDED for Crohn's disease, microbiome features at baseline may influence who achieves sustained remission. Understanding these links could help personalize...
Antibiotics can change the gut microbiome in ways that may raise IBD risk or worsen disease for some people. Knowing which antibiotic classes and approaches may be less harmful could help patients and clinicians reduce...
If fecal GP2 reliably reflects UC activity and microbial changes, it could become a noninvasive marker to track inflammation or to study disease mechanisms that differ between UC and CD.
The study suggests a multi-component herbal formula may affect inflammation, the intestinal barrier, epithelial repair, the gut microbiome, and fecal metabolites in a mouse colitis model—topics relevant to understanding...
People with ulcerative colitis may be interested because ferulic acid is a plant-derived compound that, in lab and animal studies, appears to reduce gut inflammation, support the intestinal barrier, and positively...
FUT2 connects genetics, mucosal sugars, and the gut microbiome — pathways that could help explain why some people with IBD have different microbiomes or disease risk. If validated in trials, FUT2-targeted or...
The study identifies a specific polysaccharide fraction (VPS-30) that reduced inflammation and improved gut barrier markers in cell and mouse models of colitis, suggesting a possible new functional-food lead for...
The review examines whether removing the appendix could change the course of ulcerative colitis — a potential surgical option that might lower colectomy or hospitalization risk in some scenarios but also carries...
The study suggests Artemisia rupestris extract can reduce inflammation, repair the intestinal barrier, and shift the gut microbiota and metabolites in a mouse colitis model — pathways that are important in IBD. These...
People with IBD may be interested because the review describes a probiotic (L. plantarum) and synbiotic approaches that could influence gut inflammation, barrier function, and microbiota—areas directly relevant to IBD...
AI could help identify dietary patterns, predict which patients might benefit from specific nutrition approaches, and provide personalized nutrition support — potentially improving inflammation and gut microbiome...
This research describes a new nanoparticle/hydrogel delivery system that reduced inflammation and helped restore the intestinal barrier in mouse models of ulcerative colitis. It suggests a potential future therapeutic...
People with ulcerative colitis may be interested because synbiotic approaches aim to change the gut microbiome and intestinal barrier and therefore could become a future therapeutic option or adjunct. The paper...
The paper suggests that loss of microbial bile acid transformations in IBD reduces activation of the TGR5 receptor, and that lower TGR5 bioactivity correlates with higher inflammatory activity — a potential mechanism...
The study identifies a plant-derived compound that reduced inflammation and liver injury in a mouse model of ulcerative colitis and ties its effects to both JAK2/STAT1 inhibition and changes in the gut microbiota—two...
The study describes a new oral nanotherapy that delivered apremilast to the inflamed colon in mice and reportedly reduced gut inflammation and behaviors resembling anxiety/depression—suggesting a combined...
The study describes a new oral, colon‑targeted delivery system that improved outcomes in a mouse model of ulcerative colitis and shifted immune and microbiome markers—research that could inform future therapies focused...
People with Crohn’s disease often have disrupted gut microbiomes; this trial tests a food-based approach (cranberry powder) that could potentially encourage beneficial bacteria and reduce inflammation, which is of direct...
Researchers exploring new anti-inflammatory or antioxidant compounds for ulcerative colitis may find sanggenol L’s effects on Nrf2/HO-1 and TLR4/p65 signalling of interest. Patients should note this is early-stage,...
